Cannabidiol reduces convulsive seizure frequency in DS


• The trial met its primary endpoint, demonstrating that CBD (20 mg/kg/day), as an add-on to standard of care, produced significantly greater reductions in convulsive seizures vs. placebo in patients with Dravet syndrome (DS).

• CBD resulted in significantly greater reductions in total seizure frequency vs. placebo.

• Compared to placebo, CBD caregivers were significantly more likely to report an improvement in overall condition, as measured on the Caregiver Global Impression of Change (CGIC) scale.

• CBD resulted in more adverse events than placebo, but it was generally well tolerated.